Gupta, CEO, Lord’s Mark Microbiotech , “By the end of the second quarter next year, we aim to establish 1,000 collection centers offering accurate and affordable diagnostics using advanced technologies.” – Subodh
Subodh Gupta, CEO, Lord’s Mark Microbiotech, discusses innovative healthcare solutions that address rural challenges, advance preventive care, and leverage Indigenous R&D for India’s healthcare revolution.
The COVID-19 pandemic served as a wake-up call for India’s healthcare sector, exposing critical gaps in infrastructure and sparking a wave of innovation. Subodh Gupta, CEO of Lord’s Mark Microbiotech, explains how his company is leveraging technology and indigenous R&D to tackle these challenges and revolutionise healthcare delivery nationwide.
“During the pandemic, the shortage of ventilators highlighted our reliance on imports,” Gupta recalls. “Today, domestic industries not only meet demand but also develop world-class technologies.” Over the past five years, this evolution has catalysed rapid growth in the MedTech sector, with Lord’s Mark playing a pivotal role in preventive and diagnostic healthcare.
Innovation for Masses
One of the company’s groundbreaking innovations is a portable early oral cancer detection device. “Oral cancer is prevalent in rural India, where diagnosis often requires biopsies accessible only at advanced care centers,” Gupta explains. “Our device identifies oral cancer in its earliest stages within 15 minutes, bringing critical care to underserved areas,” he adds. Prevention is another cornerstone of the company’s mission.
The company’s preventive genomics test assesses risks for chronic diseases like heart conditions, diabetes, and certain cancers before symptoms appear. “Early intervention through lifestyle changes can prevent or delay these conditions,” Gupta emphasises.
In the diagnostics space, the company is scaling its reach through a growing network of pathology centers under the brand Lord’s Pathology. “By the end of the second quarter next year, we aim to establish 1,000 collection centers offering accurate and affordable diagnostics using advanced technologies,” Gupta reveals.
The innovation driving Lord’s Mark Microbiotech stems from in-house R&D and strategic collaborations with institutions like IIT Mumbai and the Department of Atomic Energy. “These partnerships enable us to commercialise tested technologies and refine them for greater accuracy and affordability,” Gupta says. A significant milestone, he notes, is that “our biochemistry reagents are the only ones in India that can claim 100% accuracy.”
Indigenous Push
Healing through indigenous RD & Innovation
Government initiatives also play an important role. Gupta commends the establishment of MedTech parks, such as the one in Vizag, and favourable policies promoting Indigenous innovation. “Technologies from Europe or North America often don’t address India’s unique challenges. Developing homegrown solutions is key,” he emphasises.
Looking ahead, Gupta envisions a paradigm shift in healthcare, with personalised treatment models replacing the traditional one-size-fits-all approach. “India is now a hub of innovation, sharing technologies globally,” he notes. Lord’s Mark’s indigenously developed oncology device is a testament to this, drawing interest from Western markets.
(DISCLAIMER: The views expressed are solely of the author and ETHealthworld.com does not necessarily subscribe to it. ETHealthworld.com shall not be responsible for any damage caused to any person/organisation directly or indirectly).
